RT indications, age at RT exposure, and latencies
| Primary diagnosis . | Number of patients . | Median age at RT (range, y) . | Median latency, y (IQR) . |
|---|---|---|---|
| Nonmalignant* | 5 | 21 (7-40) | 6 (3-10) |
| Hematologic cancer† | 4 | 45 (32-51) | 2 (2-4) |
| Solid tumor | |||
| Prostate/testicular | 44 | 69 (41-80) | 6 (3-9) |
| Breast | 31 | 64 (32-83) | 6 (3-9) |
| Gynecologic | 15 | 55 (20-82) | 8 (3-11) |
| Head and neck | 4 | 61 (47-64) | 9 (2-15) |
| Thyroid | 3 | 58 (0-77) | 32 (18-46) |
| Lung | 2 | 66 (58, 73) | 3 |
| Medulloblastoma | 1 | <1 | 45 |
| Total | 109 | 64 (0-83) | 6.5 (3-11) |
| Primary diagnosis . | Number of patients . | Median age at RT (range, y) . | Median latency, y (IQR) . |
|---|---|---|---|
| Nonmalignant* | 5 | 21 (7-40) | 6 (3-10) |
| Hematologic cancer† | 4 | 45 (32-51) | 2 (2-4) |
| Solid tumor | |||
| Prostate/testicular | 44 | 69 (41-80) | 6 (3-9) |
| Breast | 31 | 64 (32-83) | 6 (3-9) |
| Gynecologic | 15 | 55 (20-82) | 8 (3-11) |
| Head and neck | 4 | 61 (47-64) | 9 (2-15) |
| Thyroid | 3 | 58 (0-77) | 32 (18-46) |
| Lung | 2 | 66 (58, 73) | 3 |
| Medulloblastoma | 1 | <1 | 45 |
| Total | 109 | 64 (0-83) | 6.5 (3-11) |